Table 1. Accuracy of direct MTBDRplus and MTBDRsl testing for TB and phenotypic second-line drug resistance in sputum of Xpert-positive rifampicin-resistant patients. Data are % (n/N) 95% CI.
| Overall | Smear-positive | Smear-negative | |||||
|---|---|---|---|---|---|---|---|
| Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity | ||
| MTBDRplus | TB | 88 (751/849) 86-90 |
43 (40/93) 32-53 |
97 (363/373) 94-98 |
36 (4/11) 10-69 |
82 (388/476) 77-84 *p<0.001 |
44 (36/82) 32-54 *p=0.635 |
| MTBDRsl | TB | 82 (696/849) 79-84 †p<0.001 |
51 (47/93) 32-54 †p=0.303 |
93 (347/373) 90-95 †p=0.006 |
73 (8/11) 39-93 †p=0.086 |
73 (349/476) 69-77 *p<0.001 †p=0.002 |
48 (39/82) 36-58 *p=0.117 †p<0.001 |
| Fluoroquinolones | 87 (71/82) 77-93 |
93 (297/321) 90-96 |
89 (40/45) 75-96 |
92 (180/195) 88-96 |
84 (31/37) 67-93 *p=0.105 |
93 (117/126) 89-98 *p=0.855 |
|
| Second-line injectables drugs | 84 (32/38) 68-93 **p=0.720 |
94 (317/339) 90-95 **p=0.820 |
86 (19/22) 65-97 **p=0.001 |
97 (205/212) 93-98 **p=0.108 |
81 (13/16) 54-95 *p=0.011 **p=0.821 |
88 (112/127) 81-93 *p=0.002 **p=0.052 |
|
| Fluoroquinolone and second-line injectable drugs | 70 (19/27) 69-98 |
97 (257/264) 94-98 |
85 (11/13) 54-98 |
97(165/169) 94-99 |
57 (8/14) 28-82 *p=0.118 |
97 (92/95) 91-99 *p=0.701 |
|
*
Within row comparisons between smear statuses
**
Within column comparisons for second-line injectables vs. fluoroquinolones
†
Within column comparisons for MTBDRsl vs. MTBDRplus